Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week...

Oramed Pharmaceuticals to Present at the 8th National Life Science &
Technology Week ILSI -BIOMED Conference, Israel 2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.
(OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery
systems, announced that Oramed was chosen to present at the 8th National Life
Science & Technology Week ILSI-BIOMED Conference, Israel 2009. The
presentation will be given by Mr. Nadav Kidron, President and CEO of Oramed,
on Tuesday, June 16th during the BioPharma Session at 12:30 p.m. (local time)
at the David Intercontinental Hotel in Tel-Aviv, Israel.
"The selection of Oramed as one of the companies to present at the
ILSI-Biomed is a great opportunity that allows us to present our company to
the leading biomedical, health care and life science professionals from all
over the world," said Nadav Kidron, Oramed CEO.
For more information about the upcoming ILSI Biomed conference, please
visit http://www2.kenes.com/biomed/Pages/Home.aspx
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.
Company and Business Development Contacts:
Oramed Pharmaceuticals
Tara Horn
Office: +972-2-566-0001
Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Company and Business Development Contacts: Oramed Pharmaceuticals, Tara Horn,
Office: +972-2-566-0001, Email: tara@oramed.com